Non-alcoholic steatohepatitis: physiopathological, clinical and therapeutic implications

Pérez-Aguilar, F; Benlloch, Salvador; Berenguer, Marina; Beltrán, Belén; Berenguer, J

doi:10.4321/s1130-01082004000900006

Cited by 8 publications

(4 citation statements)

References 109 publications

(241 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oxidative stress and lipid peroxidation produce many reactive oxygen species which can trigger production of various inflammatory cytokines, including TNF- α [ 23 ]. There is evidence suggesting that TNF- α plays a role in the evolution of NASH because the expressions of TNF- α and its receptor increase in patients with NASH compared to patients without NASH [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγin a Rat Model

Susutlertpanya

Werawatganon

Siriviriyakul

et al. 2015

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Nonalcoholic steatohepatitis (NASH) has become a global chronic liver disease, but no effective medicine has been proven to cure it. This study investigated the protective effects of genistein, a phytoestrogen, on NASH and examined whether it has any effect on hepatic PPARγ. Male Sprague-Dawley rats were divided into four groups: control group fed ad libitum with standard rat diet, NASH group fed ad libitum with high-fat diet to induce NASH and NASH + Gen8 group and NASH + Gen16 group fed with high-fat diet plus intragastric administration of 8 or 16 mg/kg genistein once daily. After 6 weeks, liver samples were collected to determine MDA, TNF-α, PPARγ, and histopathology. The findings were that levels of hepatic MDA and TNF-α increased in NASH group, but 16 mg/kg genistein reduced these levels significantly. Downregulation of hepatic PPARγ was observed in NASH group, but genistein significantly upregulated the expression of PPARγ in both NASH + Gen groups. The histological appearance of liver in NASH group presented pathological features of steatohepatitis which were diminished in both NASH + Gen groups. The results suggest that genistein attenuates the liver histopathology of NASH with upregulation of hepatic PPARγ, reduction of oxidative stress, and inhibition of inflammatory cytokine.

show abstract

Section: Discussionmentioning

confidence: 99%

Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγin a Rat Model

Susutlertpanya

Werawatganon

Siriviriyakul

et al. 2015

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…This rate escalates among individuals diagnosed with type 2 diabetes mellitus, where it is observed to vary from 42.6-69%. This data underscores the intertwined nature of metabolic diseases and the critical role of insulin resistance in the development of NAFLD [7,8].…”

Section: Introductionmentioning

confidence: 60%

The Contribution of Non-Alcoholic Fatty Liver Disease to the Progression of Atherosclerosis

Sadikova,

Khodjaeva

2024

tajmspr

View full text Add to dashboard Cite

In the context of insulin resistance syndrome, which encompasses changes in lipid and carbohydrate metabolism, liver-related issues are now being closely examined alongside cardiovascular diseases. Our research aimed to evaluate the predictive importance of non-alcoholic fatty liver disease (NAFLD) for identifying the likelihood of early atherosclerotic alterations in the carotid arteries. We discovered a connection between NAFLD and initial signs of atherosclerosis. By ranking prognostic factors that affect changes in the carotid artery wall, we've been able to develop a method for estimating individual atherosclerosis risk in people who are otherwise healthy. The practical value of our findings underscores the need for in-depth evaluation of individuals with NAFLD to identify risk factors that may contribute to the advancement of both liver and cardiovascular diseases.

show abstract

“…Se han evaluado estudios aleatorizados, diagnosticados por biopsia hepática, donde los efectos de la metformina se asociaron con una mejoría de los índices de la función hepática (GPT-GOT), de la sensibilidad a la insulina, péptido C, glucosa plasmática, el IMC y el colesterol plasmático. Nuestro estudio también confirma que los pacientes tratados con metformina tienen menor probabilidad de aparición de EHNA que los no tratados (24)(25)(26)(27)(28).…”

Section: Discussionunclassified

Esteatosis hepática no alcohólica y factores de riesgo cardiovascular en atención primaria

Martínez

Albero

Montes

et al. 2017

Rev. Colomb. Gastroenterol.

View full text Add to dashboard Cite

Varias circunstancias motivan el creciente interés por la esteatosis hepática no alcohólica (EHNA): la elevada prevalencia de la enfermedad en el mundo occidental, su capacidad de progresión a formas histológicas más agresivas y su asociación con enfermedades que incrementan el riesgo cardiovascular. Objetivo: analizar la relación de la esteatosis hepática no alcohólica con los factores de riesgo cardiovascular en pacientes con criterios de síndrome metabólico. Método: fue realizado un estudio descriptivo transversal con una muestra de 100 pacientes, con 2 o más factores de riesgo cardiovascular, con nula o baja ingesta de alcohol, que acudían a consulta de atención primaria. A los seleccionados se les solicitó analítica completa e interconsulta para ecografía de abdomen completo. Se evaluó si tenían esteatosis hepática; en caso de ser afirmativo, se estratificaba en 3 grados. Se recogieron las siguientes variables tanto cualitativas (sexo, antecedentes per- sonales y familiares de diabetes, hipertensión arterial, dislipidemia, entre otros) y cuantitativas (edad, peso, talla, índice de masa corporal, tratamiento farmacológico, cifras de distintos parámetros analíticos, cifras de tensión arterial y perímetro abdominal). Resultados: participaron 100 pacientes, 56% de los cuales eran mujeres, con una edad media de 61,84 DE ± 9,5 años. Del total de sujetos del estudio, el 23 % no tenía estea- tosis hepática no alcohólica; un 29% tenía esteatosis hepática leve; otro 29%, esteatosis hepática moderada; y el 19% restante, esteatosis hepática severa. En los hombres, el 82% presentó esteatosis hepática. De las mujeres, el 28,57% no presentó hígado graso. Un 22% tenía sobrepeso y un 38% de los pacientes eran obesos. Solo un 22% y un 18% tenían alteradas las cifras tensionales sistólica y diastólica, respectivamente. El 60% tenía una glucemia basal alterada. En cuanto a los parámetros lipídicos, el 36% tenía hipertrigliceride- mia; el 41%, hipercolesterolemia, con un 65% de colesterol LDL alto y un 16% de colesterol HDL bajo. El 83% de los pacientes tenía 2 o más criterios de síndrome metabólico. Conclusiones: hay una estrecha relación entre la aparición de esteatosis hepática no alcohólica y los factores de riesgo cardiovascular en pacientes con síndrome metabólico, por lo que se recomienda que, ante la aparición de estos, se analice el hígado.

show abstract

Non-alcoholic steatohepatitis: physiopathological, clinical and therapeutic implications

Cited by 8 publications

References 109 publications

Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγin a Rat Model

Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγin a Rat Model

The Contribution of Non-Alcoholic Fatty Liver Disease to the Progression of Atherosclerosis

Esteatosis hepática no alcohólica y factores de riesgo cardiovascular en atención primaria

Contact Info

Product

Resources

About